Bayer Aktiengesellschaft

Bayer Pharmaceuticals Corporation

Timothy Lowinger

William Johnston Scott

Hiroshi Komura

Roger Astbury Smith

Jacques P Dumas

Bernd Riedl

Jill E Wood

Uday R Khire

Toshiki Murata

Takashi Yoshino

Tsutomu Masuda

Mitsuyuki Shimada

Karl Ziegelbauer

Nagahiro Yoshida

Takuya Shintani

Kinji Fuchikami

Masaomi Umeda

Muneto Mogi

Martha E Rodriguez

Margaret Ann Popp

Robert Sibley

Yuji Koriyama

Ming Wang

Noriyuki Yamamoto

Takeshi Yura

Hiroki Sato

Toshio Kokubo

Yingfu Li

Scott Miller

Mary-Katherine Monahan

Joel Renick

Sachiko Sakakibara

Hiroshi Kadono

Arnel B Concepcion

Reina Natero

Makiko Marumo

Norihiro Kawamura

Hiroko Yoshino

Sachiko Sasaki

Yuka Ikegami

Makoto Shimazaki

Gyoonhee Han

Aniko M Redmann

The invention relates to the use of a group of aryl ureas in treating raf mediated diseases and pharmaceutical compositions for use in such therapy of the formula 

Hydroxy, &#x3c9;-carboxyaryl substituted diphenyl ureas and dirivatives thereof as raf kinase inhibitors

4-aryl pyrimidine compounds of general formula and salts thereof: wherein X is CH or N; R1 is hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, etc.; R2 is hydrogen or hydroxy; R3 is hydrogen, C1-6 alkyl, etc.; R4 is hydrogen, hydroxy, halogen, amino, etc.; R5 is hydroxy, amino, carboxy, etc.; R6 is hydrogen, carbamoyl, cyano, carboxy, C1-6 alkoxycarbonyl, etc. and R7 is amino or C1-6 alkanoylamino. The compounds (I) or the salts thereof have an excellent anti-inflammatory activity and the like.

4-6-diphenyl pyridine derivatives as antiinflammatory agents

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

&#x3c9;-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

Pyridine compounds of general formula:wherein &#x2014;Rrepresentsin which Ris hydrogen, Calkyl, halogen, hydroxy, Calkoxy, nitro, amino, Calkylsulfonylamino, Calkoxycarbonyl, Calkylamino, di (Calkyl)amino, Calkanoylamino, phenyl Calkylamino, phenylsulfonylamino, or &#x2014;O&#x2014;(CH)&#x2014;R; Rrepresents hydrogen or halogen; Rrepresents 1.2.3.6-tetrahydro-pyridine, or &#x2014;CRRRwherein Rrepresents H or Calkyl and Rand Rare joined to form a 5-8 membered saturated ring optionally containing up to three heteroatoms; Ris carbamoyl, CN, carboxyl, etc.; Ris amino, Calkylamino, di Calkylamino, etc. or salt thereof. The compound has an excellent anti-inflammatory activity, and other biological activity.

Pyridine derivatives

A compound of the formula (I)in which Ris &#x2014;OR, &#x2014;SR, &#x2014;SOR, &#x2014;SOR, &#x2014;NHR, or &#x2014;NRR, and R, R, and Rare as defined broadly in the text. Ris H, C-Calkyl, carbamoyl, or an ester group. Ris thienyl, pyridyl optionally substituted by halogen or C-Calkoxy; naphthyl optionally substituted by C-Calkoxy; dioxane fused phenyl; dioxacyclopentane fused phenyl; or optionally substituted phenyl. Y is CH or N. A process for preparing such compounds, pharmaceutical compositions containing such compounds, and a method of treating asthma using them are also disclosed and claimed.

Imidazopyrimidine derivatives and triazolopyrimidine derivatives

Growing community of inventors

Wuppertal, Germany

Timothy Lowinger